Cargando…

Selinexor and the Selective Inhibition of Nuclear Export: A New Perspective on the Treatment of Sarcomas and Other Solid and Non-Solid Tumors

Nucleocytoplasmic transport has been found dysregulated in many types of cancer and is often described as a poor prognostic factor. Specifically, Exportin-1 (XPO1) has been found overexpressed in many tumors and has become an attractive target in molecular oncology and therapeutics development. The...

Descripción completa

Detalles Bibliográficos
Autores principales:	Marretta, Antonella Lucia, Di Lorenzo, Giuseppe, Ribera, Dario, Cannella, Lucia, von Arx, Claudia, Bracigliano, Alessandra, Clemente, Ottavia, Tafuto, Roberto, Pizzolorusso, Antonio, Tafuto, Salvatore
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8466603/ https://www.ncbi.nlm.nih.gov/pubmed/34575598 http://dx.doi.org/10.3390/pharmaceutics13091522

Ejemplares similares

Response to Peptide Receptor Radionuclide Therapy in Pheocromocytomas and Paragangliomas: A Systematic Review and Meta-Analysis
por: Marretta, Antonella Lucia, et al.
Publicado: (2023)

Is immunotherapy in the future of therapeutic management of sarcomas?
por: Clemente, Ottavia, et al.
Publicado: (2021)

Multidisciplinary Management of Retroperitoneal Sarcoma: Diagnosis, Prognostic Factors and Treatment
por: Carbone, Fabio, et al.
Publicado: (2021)

One‐way endobronchial valves in the management of complex persistent air leaks in a soft tissue sarcoma patient
por: Fiorelli, Alfonso, et al.
Publicado: (2023)

Malignant Sinonasal Tumors: Update on Histological and Clinical Management
por: Bracigliano, Alessandra, et al.
Publicado: (2021)

The Impact of O6-Methylguanine-DNA Methyltransferase (MGMT) Promoter Methylation on the Outcomes of Patients with Leiomyosarcoma Treated with Dacarbazine
por: Cannella, Lucia, et al.
Publicado: (2023)

Effect of Octreotide Long-Acting Release on Tregs and MDSC Cells in Neuroendocrine Tumour Patients: A Pivotal Prospective Study
por: von Arx, Claudia, et al.
Publicado: (2020)

Nuclear Export Inhibitor Selinexor Enhances Oncolytic Myxoma Virus Therapy against Cancer
por: Rahman, Masmudur M., et al.
Publicado: (2023)

Selinexor in combination with standard chemotherapy in patients with advanced or metastatic solid tumors
por: Thein, Kyaw Z., et al.
Publicado: (2021)

XPO1 inhibition with selinexor synergizes with proteasome inhibition in neuroblastoma by targeting nuclear export of IkB
por: Galinski, Basia, et al.
Publicado: (2021)

Selinexor, a selective inhibitor of nuclear export, inhibits human neutrophil extracellular trap formation in vitro
por: Baron, Szilvia, et al.
Publicado: (2022)

Longitudinal tracking of single live cancer cells to understand cell cycle effects of the nuclear export inhibitor, selinexor
por: Marcus, Joshua M., et al.
Publicado: (2015)

The Nuclear Export Inhibitor Selinexor Inhibits Hypoxia Signaling Pathways And 3D Spheroid Growth Of Cancer Cells
por: Depping, Reinhard, et al.
Publicado: (2019)

Preclinical activity of selinexor, an inhibitor of XPO1, in sarcoma
por: Nakayama, Robert, et al.
Publicado: (2016)

Proteomics identify nuclear export as a targetable pathway in neuroblastoma: Comment on “XPO1 inhibition with selinexor synergizes with proteasome inhibition in neuroblastoma by targeting nuclear export of IκB”
por: Shah, Nilay
Publicado: (2021)

Overview of systemic therapy options in liposarcoma, with a focus on the activity of selinexor, a selective inhibitor of nuclear export in dedifferentiated liposarcoma
por: Thirasastr, Prapassorn, et al.
Publicado: (2022)

Selinexor, a novel selective inhibitor of nuclear export, reduces SARS-CoV-2 infection and protects the respiratory system in vivo
por: Kashyap, Trinayan, et al.
Publicado: (2021)

Toward a Personalized Therapy in Soft-Tissue Sarcomas: State of the Art and Future Directions
por: Montella, Liliana, et al.
Publicado: (2021)

Lenvatinib, a molecule with versatile application: from preclinical evidence to future development in anti-cancer treatment
por: Capozzi, Monica, et al.
Publicado: (2019)

A Phase II Trial of Selinexor, an Oral Selective Inhibitor of Nuclear Export Compound, in Abiraterone‐ and/or Enzalutamide‐Refractory Metastatic Castration‐Resistant Prostate Cancer
por: Wei, Xiao X., et al.
Publicado: (2018)

1109P The psychological impact of COVID-19 pandemic on patients with NETs: Between resilience and vulnerability
por: Lauricella, E., et al.
Publicado: (2021)

Selinexor for multiple myeloma
Publicado: (2022)

Selinexor, a selective inhibitor of nuclear export, enhances the anti-tumor activity of olaparib in triple negative breast cancer regardless of BRCA1 mutation status
por: Marijon, Hélène, et al.
Publicado: (2021)

3355 The CTSA Institutional website: A higher purpose - Researcher use of institutional Clinical and Translational Science Award (CTSA) website content to assess or promote NCATS CTSA Program Goals.
por: Tafuto, Barbara Ann
Publicado: (2019)

Aberrant Expression of Long Non Coding RNA HOTAIR and De-Regulation of the Paralogous 13 HOX Genes Are Strongly Associated with Aggressive Behavior of Gastro-Entero-Pancreatic Neuroendocrine Tumors
por: Di Mauro, Annabella, et al.
Publicado: (2021)

Safety and Activity of Metronomic Temozolomide in Second-Line Treatment of Advanced Neuroendocrine Neoplasms
por: Tafuto, Salvatore, et al.
Publicado: (2019)

Updates on the Role of Molecular Alterations and NOTCH Signalling in the Development of Neuroendocrine Neoplasms
por: von Arx, Claudia, et al.
Publicado: (2019)

Integration of Massage Therapy in Outpatient Cancer Care
por: Cowen, Virginia S., et al.
Publicado: (2018)

76 Methods and Perceptions of Success for Patient Recruitment in Decentralized Clinical Trials
por: Tafuto, Barbara, et al.
Publicado: (2023)

Selinexor in combination with carboplatin and paclitaxel in patients with advanced solid tumors: Results of a single-center, multi-arm phase Ib study
por: Thein, Kyaw Z., et al.
Publicado: (2021)

Selinexor, a Selective Inhibitor of Nuclear Export (SINE) compound, acts through NF-κB deactivation and combines with proteasome inhibitors to synergistically induce tumor cell death
por: Kashyap, Trinayan, et al.
Publicado: (2016)

271 Search Solutions: Investigation into CTSA Hubs COVID-19 Vaccine Information
por: Bashir, Hasan M., et al.
Publicado: (2022)

Selinexor in combination with topotecan in patients with advanced or metastatic solid tumors: Results of an open-label, single-center, multi‐arm phase Ib study
por: Thein, Kyaw Zin, et al.
Publicado: (2021)

Correction to: Selinexor in combination with carboplatin and paclitaxel in patients with advanced solid tumors: results of a single‑center, multi‑arm phase Ib study
por: Thein, Kyaw Z., et al.
Publicado: (2021)

Selinexor, a selective inhibitor of nuclear export (SINE), shows enhanced activity in combination with PD-1/PD-L1 blockade in syngeneic murine models of colon cancer and melanoma
por: Farren, Matthew R, et al.
Publicado: (2015)

A phase 1 study of the safety, pharmacokinetics and pharmacodynamics of escalating doses followed by dose expansion of the selective inhibitor of nuclear export (SINE) selinexor in Asian patients with advanced or metastatic malignancies
por: Ho, Jingshan, et al.
Publicado: (2022)

Selinexor in relapsed/refractory multiple myeloma
por: Richter, Joshua, et al.
Publicado: (2020)

Selinexor and COVID-19: The Neglected Warden
por: Mostafa-Hedeab, Gomaa, et al.
Publicado: (2022)

Correction to: Selinexor in combination with topotecan in patients with advanced or metastatic solid tumors: Results of an open-label, single-center, multi-arm phase Ib study
por: Thein, Kyaw Zin, et al.
Publicado: (2021)

62610 Effects of electronic verses paper based data capture in large multinational trials on time to complete, time to publication, participation and collaboration.
por: Davidoff, Erika, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_b79u12h63in4g6uipqsnd8kalg